Abstract
In a matched-pair study, we analyzed the association of a phenotypically relevant NQO1 polymorphism (C609T) with risk of secondary malignant neoplasms (SMN) after treatment for childhood acute lymphoblastic leukemia. Patients carrying a variant low-activity NQO1 allele had a significantly increased risk of developing a SMN. The observed effect was restricted to solid tumors.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols
-
Asparaginase
-
Child
-
Child, Preschool
-
Daunorubicin
-
Female
-
Humans
-
Infant
-
Male
-
Matched-Pair Analysis
-
NAD(P)H Dehydrogenase (Quinone) / genetics*
-
Neoplasms, Second Primary / genetics*
-
Polymorphism, Genetic*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Prednisone
-
Vincristine
Substances
-
Vincristine
-
NAD(P)H Dehydrogenase (Quinone)
-
NQO1 protein, human
-
Asparaginase
-
Prednisone
-
Daunorubicin